(RTTNews) – Novavax Inc. (NVAX) announced Monday that its coronavirus vaccine candidate received accelerated designation from the US Food and Drug Administration. But it’s not the first time
NVX-CoV2373, the company’s COVID-19 vaccine, is recently in complex clinical development. NVXCoV2373 is a solid prefusion protein manufactured with Novavax nanoparticle generation and includes its patented MatrixM adjuvant.
“The FDA’s decision to grant the Fast Track designation for NVX-CoV2373 reflects the urgent desire for an effective vaccine to save you COVID-19, and we look forward to working intensively with the company to increase access to this vaccine,” said Gregory Glenn, President of Research and Development, Novavax.
Novavax said he plans to begin his critical Phase 3 clinical trial in the United States and Mexico until the end of November.
FDA approval occurs on the same day Pfizer announced that its coronavirus vaccine candidate had a 90% efficacy rate in complex trials. The company is contemplating FDA emergency use authorization.
NVAX has recently 91. 87, an increase of $2. 01 or 2. 24% on the Nasdaq.